Browse CDA

Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00383 Cytidine and deoxycytidylate deaminase zinc-binding region
Function

This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0006140 regulation of nucleotide metabolic process
GO:0006206 pyrimidine nucleobase metabolic process
GO:0006213 pyrimidine nucleoside metabolic process
GO:0006216 cytidine catabolic process
GO:0008655 pyrimidine-containing compound salvage
GO:0009112 nucleobase metabolic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009164 nucleoside catabolic process
GO:0009972 cytidine deamination
GO:0016049 cell growth
GO:0019439 aromatic compound catabolic process
GO:0019858 cytosine metabolic process
GO:0030308 negative regulation of cell growth
GO:0034655 nucleobase-containing compound catabolic process
GO:0042454 ribonucleoside catabolic process
GO:0043094 cellular metabolic compound salvage
GO:0043097 pyrimidine nucleoside salvage
GO:0043174 nucleoside salvage
GO:0044270 cellular nitrogen compound catabolic process
GO:0045926 negative regulation of growth
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046087 cytidine metabolic process
GO:0046131 pyrimidine ribonucleoside metabolic process
GO:0046133 pyrimidine ribonucleoside catabolic process
GO:0046134 pyrimidine nucleoside biosynthetic process
GO:0046135 pyrimidine nucleoside catabolic process
GO:0046700 heterocycle catabolic process
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901657 glycosyl compound metabolic process
GO:1901658 glycosyl compound catabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004126 cytidine deaminase activity
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016814 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines
GO:0019239 deaminase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00240 Pyrimidine metabolism
hsa00983 Drug metabolism - other enzymes
hsa01100 Metabolic pathways
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-6798695: Neutrophil degranulation
R-HSA-73848: Pyrimidine metabolism
R-HSA-73614: Pyrimidine salvage reactions
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CDA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20404277PlasmacytomaInhibit immunity; Resistant to immunotherapyIn this study, we report that small interfering RNA silencing of AID in plasmacytoma dramatically increased its susceptibility to immunotherapy by CTLs. Gene-array analysis showed dramatically altered expression of a number of genes in AID-silenced plasmacytoma cells, and upregulation of CD200 was shown to be in favor of tumor eradication by CTLs.
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.210.648
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0160.987
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3840.58
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1950.721
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0160.266
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8490.416
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1240.834
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0260.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3240.725
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3330.168
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7290.668
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1560.438
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDA
Namecytidine deaminase
Aliases cytosine nucleoside deaminase; small cytidine deaminase
Chromosomal Location1p36.2-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CDA.
ID Name Drug Type Targets #Targets
DB031851-Beta-Ribofuranosyl-1,3-DiazepinoneSmall MoleculeCDA1